Purpose: To analyze the histopathological changes in eyelash following electroepilation using radiofrequency (RF) cautery.

Methods: RF current was applied to the eyelash root in human eyelids (from exenteration or eyelid shortening procedures) at a pre-determined depth of 3 mm excision a-priori, and processed for routine histology. Studied parameters were the extent of necrosis, involvement of the eyelash bulb, and type of bulb damage (partial or whole necrosis). Also, seven patients of chronic cicatrizing conjunctivitis with trichiasis ( = 4) and distichiasis ( = 3) underwent electroepilation using the above RF protocol.

Results: Twelve eyelid specimens of seven patients (mean age 40 years; five upper eyelid and seven lower eyelid) were evaluated histologically. Majority of specimens (92%) showed coagulative necrosis in the eyelash bulb, follicle, orbicularis oculi, adjacent nerves, and blood vessels. The mean depth of necrosis was 2.12 ± 0.63 mm. Of 12, eleven eyelash bulbs showed necrotic changes with only partial bulb involvement in 55% of eyelids. The horizontal extent of coagulative necrosis was not uniform across the lash track, and the majority showed a wider area of damage in the lower segment. Of seven, all patients with trichiasis (4/4) showed no recurrence of lash misdirection whereas 66% of distichiasis patients (2/3) showed recurrent lash growth with one sitting of electroepilation applied at 3 mm.

Conclusions: Electroepilation guided by RF current produces variable necrotic changes in the eyelash root, leaving portions of intact bulbs in half of the eyelids.

Download full-text PDF

Source
http://dx.doi.org/10.1080/02713683.2022.2052107DOI Listing

Publication Analysis

Top Keywords

changes eyelash
8
eyelash root
8
eyelash bulb
8
coagulative necrosis
8
necrotic changes
8
eyelash
6
necrosis
5
effects needle
4
needle assisted
4
assisted radiofrequency
4

Similar Publications

Purpose: To report the design of FLuorometholone as Adjunctive MEdical therapy for TT surgery (FLAME) trial.

Design: Parallel design, double-masked, placebo-controlled clinical trial with 1:1 randomization to fluorometholone 0.1% eye drops twice daily or placebo twice daily for 4 weeks in eyes undergoing trachomatous trichiasis (TT) surgery for assessing the efficacy, safety, and cost-effectiveness of fluorometholone 0.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigated the incidence of the prostaglandin-associated periorbital syndrome (PAPS) in patients with primary open-angle glaucoma or ocular hypertension after using topical prostaglandin analogues (PGAs) for 3-6 months.
  • Among the 55 patients studied, key indicators such as interpupillary distance and exophthalmos were measured, alongside subjective assessments of periocular changes, showing significant changes primarily at the 1 and 3-month marks.
  • Results indicated that bimatoprost resulted in the highest incidence of PAPS, with noticeable periorbital changes like eyelash growth and hyperpigmentation increasing over time.
View Article and Find Full Text PDF
Article Synopsis
  • Ciprofol is a new sedative anesthetic that shows promise for older adults, particularly in reducing hypotension during anesthesia induction compared to propofol.
  • In a study of 117 older adults, ciprofol resulted in a lower incidence of hypotension (26.3%) compared to propofol (48.3%).
  • Patients receiving ciprofol also reported less injection pain and maintained stable blood pressure levels while achieving successful anesthesia induction in both groups.
View Article and Find Full Text PDF
Article Synopsis
  • The ALLEGRO study assessed the effectiveness and safety of ritlecitinib, a treatment for alopecia areata (AA), focusing on patient-reported hair loss outcomes.
  • Patients aged 12 and older with significant scalp hair loss participated in a 48-week trial comparing different dosages of ritlecitinib to a placebo.
  • Results showed that 5-36% of ritlecitinib patients reported improved hair loss after 24 weeks, which correlated with positive changes in emotional symptoms and activity limitations, indicating the treatment's beneficial effects.
View Article and Find Full Text PDF
Article Synopsis
  • The ALLEGRO studies show that ritlecitinib is effective and well-tolerated for treating alopecia areata in patients aged 12 and older for up to 24 months.
  • Results indicate significant improvement in hair regrowth, with a marked increase in patients achieving favorable Severity of Alopecia Tool (SALT) scores at both 12 and 24 months.
  • The safety profile of ritlecitinib remains consistent with previous studies, confirming its long-term tolerability for users.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!